Skip to main content
Top
Published in: Tumor Biology 6/2014

01-06-2014 | Research Article

Interaction between smoking and CYP2C19*3 polymorphism increased risk of lung cancer in a Chinese population

Authors: Fei Yan, Jin-Fu Xu, Xiao-fang Liu, Xing-Hua Li

Published in: Tumor Biology | Issue 6/2014

Login to get access

Abstract

Cytochrome P450 (CYP) 2C19 is expressed in vascular endothelium and metabolizes arachidonic acid to biologically active epoxyeicosatrienoic acids (EETs), which play a crucial role in either the detoxification or inactivation of potential carcinogens, or the bioactivation of some environmental procarcinogens to reactive DNA-binding metabolites. And smoking is a major risk factor for lung cancer. The purpose of this study is to explore the relationship between the interaction of CYP2C19*3 polymorphism and smoking and lung cancer in a Chinese population. In a Chinese case-control study of lung cancer patients (n = 420) and healthy controls (n = 420), we investigated the roles of CYP2C19*3 polymorphism in lung cancer risk using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis. We found that the frequency of CYP2C19 *3 (AG + AA) genotype was significantly higher in lung cancer patients than that in control subjects (14.28 % versus 4.76 %; P < 0.001). Multivariable logistic regression analysis showed that after adjustment of other risk factors, the A allele of CYP2C19*3 remains significantly associated with lung cancer. We also found that there was a significant interaction between CYP2C19 *3 and smoking in increasing the risk for lung cancer (OR 5.121, 95 % confidence interval [CI] 4.321–10.124; P = 0.001). The interaction between CYP2C19 *3 polymorphism and smoking plays an important role in the mechanism of lung cancer in Chinese population.
Literature
1.
2.
3.
go back to reference Liu X, Lin XJ, Wang CP, et al. Association between smoking and p53 mutation in lung cancer: a meta-analysis. Clin Oncol (R Coll Radiol). 2014;26:18–24.CrossRefPubMed Liu X, Lin XJ, Wang CP, et al. Association between smoking and p53 mutation in lung cancer: a meta-analysis. Clin Oncol (R Coll Radiol). 2014;26:18–24.CrossRefPubMed
4.
go back to reference Winkler V, Ott JJ, Cowan M, Becher H. Smoking prevalence and its impacts on lung cancer mortality in sub-Saharan Africa: an epidemiological study. Prev Med. 2013;57:634–40.CrossRefPubMed Winkler V, Ott JJ, Cowan M, Becher H. Smoking prevalence and its impacts on lung cancer mortality in sub-Saharan Africa: an epidemiological study. Prev Med. 2013;57:634–40.CrossRefPubMed
5.
go back to reference Tsou JA, Hagen JA, Carpenter CL, Laird-Offringa IA. DNA methylation analysis: a powerful new tool for lung cancer diagnosis. Oncogene. 2002;21:5450–61.CrossRefPubMed Tsou JA, Hagen JA, Carpenter CL, Laird-Offringa IA. DNA methylation analysis: a powerful new tool for lung cancer diagnosis. Oncogene. 2002;21:5450–61.CrossRefPubMed
6.
go back to reference Yamamoto N, Murakami H, Hayashi H, et al. CYP2C19 genotype-based phase I studies of a c-Met inhibitor tivantinib in combination with erlotinib, in advanced/metastatic non-small cell lung cancer. Br J Cancer. 2013;109:2803–9.PubMedCentralCrossRefPubMed Yamamoto N, Murakami H, Hayashi H, et al. CYP2C19 genotype-based phase I studies of a c-Met inhibitor tivantinib in combination with erlotinib, in advanced/metastatic non-small cell lung cancer. Br J Cancer. 2013;109:2803–9.PubMedCentralCrossRefPubMed
7.
go back to reference Gan CQ, Wang XY, Cao YD, et al. Association of CYP2C19*3 gene polymorphism with breast cancer in Chinese women. Genet Mol Res. 2011;10:3514–9.CrossRefPubMed Gan CQ, Wang XY, Cao YD, et al. Association of CYP2C19*3 gene polymorphism with breast cancer in Chinese women. Genet Mol Res. 2011;10:3514–9.CrossRefPubMed
8.
go back to reference Lim JS, Chen XA, Singh O, et al. Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients. Br J Clin Pharmacol. 2011;71:737–50.PubMedCentralCrossRefPubMed Lim JS, Chen XA, Singh O, et al. Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients. Br J Clin Pharmacol. 2011;71:737–50.PubMedCentralCrossRefPubMed
9.
go back to reference Isomura Y, Yamaji Y, Ohta M, et al. A genetic polymorphism of CYP2C19 is associated with susceptibility to biliary tract cancer. J Gastroenterol. 2010;45:1045–52.CrossRefPubMed Isomura Y, Yamaji Y, Ohta M, et al. A genetic polymorphism of CYP2C19 is associated with susceptibility to biliary tract cancer. J Gastroenterol. 2010;45:1045–52.CrossRefPubMed
10.
go back to reference Xie X, Ma YT, Yang YN, et al. Personalized antiplatelet therapy according to CYP2C19 genotype after percutaneous coronary intervention: a randomized control trial. Int J Cardiol. 2013;168:3736–40.CrossRefPubMed Xie X, Ma YT, Yang YN, et al. Personalized antiplatelet therapy according to CYP2C19 genotype after percutaneous coronary intervention: a randomized control trial. Int J Cardiol. 2013;168:3736–40.CrossRefPubMed
11.
go back to reference Xie X, Ma YT, Yang YN, et al. CYP2C19 phenotype, stent thrombosis, myocardial infarction, and mortality in patients with coronary stent placement in a Chinese population. PLoS One. 2013;8:e59344.PubMedCentralCrossRefPubMed Xie X, Ma YT, Yang YN, et al. CYP2C19 phenotype, stent thrombosis, myocardial infarction, and mortality in patients with coronary stent placement in a Chinese population. PLoS One. 2013;8:e59344.PubMedCentralCrossRefPubMed
12.
go back to reference Yang YN, Wang XL, Ma YT, et al. Association of interaction between smoking and CYP 2C19*3 polymorphism with coronary artery disease in a Uighur population. Clin Appl Thromb Hemost. 2010;16:579–83.CrossRefPubMed Yang YN, Wang XL, Ma YT, et al. Association of interaction between smoking and CYP 2C19*3 polymorphism with coronary artery disease in a Uighur population. Clin Appl Thromb Hemost. 2010;16:579–83.CrossRefPubMed
13.
go back to reference De Morais SM, Wilkinson GR, Blaisdell J, et al. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol. 1994;46:594–8.PubMed De Morais SM, Wilkinson GR, Blaisdell J, et al. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol. 1994;46:594–8.PubMed
14.
go back to reference Xing DL, Song DK, Zhang LR. Polymorphism of CYP2C19 gene in patients with bladder cancer. Zhengzhou Da Xue Xue Bao. 2006;41:285–7. Xing DL, Song DK, Zhang LR. Polymorphism of CYP2C19 gene in patients with bladder cancer. Zhengzhou Da Xue Xue Bao. 2006;41:285–7.
15.
go back to reference Mochizuki J, Murakami S, Sanjo A, et al. Genetic polymorphisms of cytochrome P450 in patients with hepatitis C virus-associated hepatocellular carcinoma. J Gastroenterol Hepatol. 2005;20:1191–7.CrossRefPubMed Mochizuki J, Murakami S, Sanjo A, et al. Genetic polymorphisms of cytochrome P450 in patients with hepatitis C virus-associated hepatocellular carcinoma. J Gastroenterol Hepatol. 2005;20:1191–7.CrossRefPubMed
Metadata
Title
Interaction between smoking and CYP2C19*3 polymorphism increased risk of lung cancer in a Chinese population
Authors
Fei Yan
Jin-Fu Xu
Xiao-fang Liu
Xing-Hua Li
Publication date
01-06-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 6/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-1689-3

Other articles of this Issue 6/2014

Tumor Biology 6/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine